Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis

European Journal of Cancer

Volumn 49, Issue 13, 2013, Pages 2900-2909

  Kalam, Kashif ^a   Marwick, Thomas H ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Anthracycline; Cancer chemotherapy; Cardioprotection; Cardiotoxicity; Trastuzumab

Indexed keywords

ANGIOTENSIN ANTAGONIST; ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RAZOXANE;

BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOTOXICITY; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HUMAN; META ANALYSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW;

EID: 84881105772     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.04.030     Document Type: Article

References (60)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2 2011 69 90
2. M. Sant, C. Allemani, M. Santaquilani, A. Knijn, F. Marchesi, and R. Capocaccia EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary Eur J Cancer 45 6 2009 931 991
3. K.C. Oeffinger, A.C. Mertens, and C.A. Sklar Chronic health conditions in adult survivors of childhood cancer N Engl J Med 355 15 2006 1572 1582
4. G. Curigliano, E.L. Mayer, H.J. Burstein, E.P. Winer, and A. Goldhirsch Cardiac toxicity from systemic cancer therapy: a comprehensive review Prog Cardiovasc Dis 53 2 2010 94 104
5. L.J. Steinherz, P.G. Steinherz, C.T. Tan, G. Heller, and M.L. Murphy Cardiac toxicity 4 to 20 years after completing anthracycline therapy JAMA 266 12 1991 1672 1677
6. M. Minami, S. Matsumoto, and H. Horiuchi Cardiovascular side-effects of modern cancer therapy Circ J 74 9 2010 1779 1786
7. D.J. Slamon, B. Leyland-Jones, and S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 11 2001 783 792
8. S.M. Shankar, N. Marina, and M.M. Hudson Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group Pediatrics 121 2 2008 e387 e396
9. S.M. Swain, F.S. Whaley, and M.S. Ewer Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials Cancer 97 11 2003 2869 2879
10. J. Saini, M.W. Rich, and A.P. Lyss Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases Ann Intern Med 106 6 1987 814 816
11. D.D. Von Hoff, M.W. Layard, and P. Basa Risk factors for doxorubicin-induced congestive heart failure Ann Intern Med 91 5 1979 710 717
12. F.V. Guimaraes-Filho, D.M. Tan, J.C. Braga, A. Rodrigues, P.H. Waib, and B.B. Matsubara Ventricular systolic reserve in asymptomatic children previously treated with low doses of anthracyclines: a longitudinal, prospective exercise echocardiography study Pediatr Blood Cancer 59 3 2012 548 552
13. E. Ho, A. Brown, and P. Barrett Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study Heart 96 9 2010 701 707
14. D. Cardinale, M.T. Sandri, and A. Martinoni Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy J Am Coll Cardiol 36 2 2000 517 522
15. V.B. Pai, and M.C. Nahata Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention Drug Saf 22 4 2000 263 302
16. S.I. Bearman, F.B. Petersen, and R.A. Schor Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity Bone Marrow Transplant 5 3 1990 173 177
17. E.A. Perez, and R. Rodeheffer Clinical cardiac tolerability of trastuzumab J Clin Oncol 22 2 2004 322 329
18. D. Cardinale, A. Colombo, and G. Lamantia Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy J Am Coll Cardiol 55 3 2010 213 220
19. Z. Acar, A. Kale, and M. Turgut Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy J Am Coll Cardiol 58 9 2011 988 989
20. M.A. Ibrahim, O.M. Ashour, Y.F. Ibrahim, H.I. El-Bitar, W. Gomaa, and S.R. Abdel-Rahim Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity Pharmacol Res 60 5 2009 373 381
21. F. de Nigris, M. Rienzo, C. Schiano, C. Fiorito, A. Casamassimi, and C. Napoli Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart Eur J Cancer 44 3 2008 334 340
22. H. Matsui, I. Morishima, Y. Numaguchi, Y. Toki, K. Okumura, and T. Hayakawa Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats Life Sci 65 12 1999 1265 1274
23. R.D. Spagnuolo, S. Recalcati, L. Tacchini, and G. Cairo Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity Br J Pharmacol 163 2 2011 299 312
24. A. Liberati, D.G. Altman, and J. Tetzlaff The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ 339 2009 b2700
25. M. Venturini, A. Michelotti, and L. Del Mastro Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer J Clin Oncol 14 12 1996 3112 3120
26. S.M. Swain, F.S. Whaley, and M.C. Gerber Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer J Clin Oncol 15 4 1997 1318 1332
27. M. Lopez, P. Vici, and K. Di Lauro Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas J Clin Oncol 16 1 1998 86 92
28. J.L. Speyer, M.D. Green, and A. Zeleniuch-Jacquotte ICRF-187 permits longer treatment with doxorubicin in women with breast cancer J Clin Oncol 10 1 1992 117 127
29. M. Marty, M. Espie, A. Llombart, A. Monnier, B.L. Rapoport, and V. Stahalova Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy Ann Oncol 17 4 2006 614 622
30. L.H. Wexler, M.P. Andrich, and D. Venzon Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin J Clin Oncol 14 2 1996 362 372
31. N. Kalay, E. Basar, and I. Ozdogru Protective effects of carvedilol against anthracycline-induced cardiomyopathy J Am Coll Cardiol 48 11 2006 2258 2262
32. S. Seicean, A. Seicean, N. Alan, J.C. Plana, G.T. Budd, and T.H. Marwick Cardioprotective effect of beta-adrenoceptor blockade in breast cancer patients undergoing chemotherapy: a follow-up study of heart failure Circ Heart Fail 2013 [Epub ahead of print]
33. S. Seicean, A. Seicean, J.C. Plana, G.T. Budd, and T.H. Marwick Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study J Am Coll Cardiol 60 23 2012 2384 2390
34. D. Cardinale, A. Colombo, and M.T. Sandri Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition Circulation 114 23 2006 2474 2481
35. H. Nakamae, K. Tsumura, and Y. Terada Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone Cancer 104 11 2005 2492 2498
36. X Bosch, M Rovira, and M Sitges Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies. The OVERCOME Trial J Am Coll Cardiol 2013 http://dx.doi.org/10.1016/j.jacc.2013.02.072.[Epub ahead of print].
37. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 3 1986 177 188
38. C. Zuppinger, F. Timolati, and T.M. Suter Pathophysiology and diagnosis of cancer drug induced cardiomyopathy Cardiovasc Toxicol 7 2 2007 61 66
39. P.K. Singal, C.M. Deally, and L.E. Weinberg Subcellular effects of adriamycin in the heart: a concise review J Mol Cell Cardiol 19 8 1987 817 828
40. B. Kalyanaraman, E. Perez-Reyes, and R.P. Mason Spin-trapping and direct electron spin resonance investigations of the redox metabolism of quinone anticancer drugs Biochim Biophys Acta 630 1 1980 119 130
41. J.H. Doroshow Effect of anthracycline antibiotics on oxygen radical formation in rat heart Cancer Res 43 2 1983 460 472
42. P.K. Singal, R.J. Segstro, R.P. Singh, and M.J. Kutryk Changes in lysosomal morphology and enzyme activities during the development of adriamycin-induced cardiomyopathy Can J Cardiol 1 2 1985 139 147
43. C. Huang, X. Zhang, and J.M. Ramil Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice Circulation 121 5 2010 675 683
44. M.S. Ewer, and S.M. Ewer Cardiotoxicity of anticancer treatments: what the cardiologist needs to know Nat Rev Cardiol 7 10 2010 564 575
45. S.E. Lipshultz, N. Rifai, and V.M. Dalton The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia N Engl J Med 351 2 2004 145 153
46. A. Riad, S. Bien, and D. Westermann Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice Cancer Res 69 2 2009 695 699
47. F.G. Dunn, W. Oigman, H.O. Ventura, F.H. Messerli, I. Kobrin, and E.D. Frohlich Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension Am J Cardiol 53 1 1984 105 108
48. L.X. Wang, M. Ideishi, E. Yahiro, H. Urata, K. Arakawa, and K. Saku Mechanism of the cardioprotective effect of inhibition of the renin-angiotensin system on ischemia/reperfusion-induced myocardial injury Hypertens Res 24 2 2001 179 187
49. J. Cheng, K. Kamiya, and I. Kodama Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential Cardiovasc Drug Rev 19 2 2001 152 171
50. M. Soga, F.A. Kamal, and K. Watanabe Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats Int J Cardiol 110 3 2006 378 385
51. H. Ishiguro, Y. Ishiguro, Y. Kubota, and H. Uemura Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action Prostate 67 9 2007 924 932
52. P.J. Oliveira, J.A. Bjork, and M.S. Santos Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity Toxicol Appl Pharmacol 200 2 2004 159 168
53. S.E. Lipshultz, S.D. Colan, R.D. Gelber, A.R. Perez-Atayde, S.E. Sallan, and S.P. Sanders Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood N Engl J Med 324 12 1991 808 815
54. A.C. Nagy, E. Tolnay, T. Nagykalnai, and T. Forster Cardiotoxicity of anthracycline in young breast cancer female patients: the possibility of detection of early cardiotoxicity by TDI Neoplasma 53 6 2006 511 517
55. J.H. Silber, A. Cnaan, and B.J. Clark Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines J Clin Oncol 22 5 2004 820 828
56. B.W. Eidem Identification of anthracycline cardiotoxicity: left ventricular ejection fraction is not enough J Am Soc Echocardiogr 21 12 2008 1290 1292
57. J.M. DeCara Early detection of chemotherapy-related left ventricular dysfunction Curr Cardiol Rep 14 3 2012 334 341
58. J. Walker, N. Bhullar, and N. Fallah-Rad Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging J Clin Oncol 28 21 2010 3429 3436
59. D. Cardinale, M.T. Sandri, and A. Martinoni Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy Ann Oncol 13 5 2002 710 715
60. D. Cardinale, M.T. Sandri, and A. Colombo Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy Circulation 109 22 2004 2749 2754